– Risk of death was reduced by 53% in patients treated with enfortumab vedotin plus pembrolizumab compared to chemotherapy –
– Enfortumab vedotin plus pembrolizumab improved median overall.
Groundbreaking EV-302 Trial Significantly Extends Overall Survival and Progression-Free Survival in Patients Treated with PADCEV® (enfortumab vedotin-ejfv) and KEYTRUDA® (pembrolizumab) in First-Line Advanced Bladder Cancer valdostadailytimes.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from valdostadailytimes.com Daily Mail and Mail on Sunday newspapers.